Arcis Biotechnology is a research and development led company with expertise in the development of a wide range of fast sample preparation technologies. We are based at Sci-tech Daresbury, UK, where we have fully equipped laboratory facilities. The Arcis Group has already developed a number of patented compounds and technologies that have been enthusiastically received in the commercial marketplace via our licensing partners.

Peter Whitehurst


A Qualified Chartered Accountant by background, Peter thrives on driving business change through an Organisation.
Peter was a key member of the SSL Executive Team that accepted a bid from Reckitt Benckiser for £2.54 billion to acquire SSL in 2010. Peter headed up the Innovation & Technology teams in SSL and a healthy track record of successful product innovations coupled with an exciting pipeline of future products helped ensure a healthy price premium for shareholders. Peter thrives on building high performing teams and giving them the remit, funds and business focus to produce exciting tangible results.

Dr Jan Rogers


Jan has extensive knowledge of the development and commercialization of innovative medical devices. She has been responsible for the introduction of New Product Development processes which have led to the successful launch of numerous products in both the healthcare and consumer markets – most notably Regent synthetic surgical gloves and the new Aquacel® woundcare  products. Jan held senior R&D positions at London International Group, Regent Medical, Molnlycke Healthcare, Convatec Inc and SSL International before joining Arcis Biotechnology in May 2011. Jan has a PhD in Surface Chemistry from the University of Reading and an MBA specializing in Innovation from the University of Bath.

Professor Steve Howell

Non-Executive Chairman

Professor Howell has over 20 years’ life science commercialisation experience, supporting companies’ development and profitability. He founded Innova Partnerships in 2006, where he has been instrumental in creating over a dozen life science start-ups and raised in excess of £100m in financing. Steve oversaw the exit of Innova Biosciences in 2016-2017 to SYGNIS AG, Innova Partnerships’ second exit. He has held positions at Unilever plc, and was previously Director of Business Development at Alere Inc. and Research Director at Unipath Ltd. In 2015 he was made Visiting Professor of Commercial Innovation at King’s College, London.